Brett Sandercock, Chief Financial Officer of ResMed Inc. (NASDAQ:RMD), sold 1,000 shares of company stock on April 1, 2026. The shares were disposed at $224.31 each, producing a total transaction value of $224,310.
Per a Form 4 filing with the Securities and Exchange Commission, the sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Sandercock adopted on February 19, 2025. After the sale, Sandercock is reported to directly hold 83,495 shares of ResMed common stock.
At the time of the report, ResMed shares were trading at $224.09, with the company carrying a market capitalization of $32.5 billion.
Investor-facing analysis available through InvestingPro highlights that ResMed retains a "GREAT" financial health score and has increased its dividend for 14 consecutive years. Those points were noted as part of the platform's Pro Research Report available to subscribers.
Separately, ResMed released its fiscal second-quarter 2026 financial results. The company reported earnings per share of $2.81, exceeding analysts' consensus estimate of $2.73. Revenue for the quarter came in at $1.4 billion, in line with expectations.
Analyst responses to the quarterly report were varied. RBC Capital increased its price target on ResMed from $311 to $314 and maintained an Outperform rating, citing double-digit growth in both revenue and earnings. KeyBanc Capital Markets likewise raised its price target, moving it from $299 to $302 and pointing to the revenue beat as supportive of its thesis.
Other brokerage firms remained more cautious. Needham reiterated a Hold rating, while noting ResMed's organic revenue growth improved to 8% in the second quarter, up from 7% in the first quarter and reversing a prior trend of slowing growth over the previous three quarters. Stifel also maintained a Hold rating with a $265 price target; that stance followed a survey of CPAP users intended to assess device usage patterns.
Taken together, the recent insider sale, the quarterly results, and the spectrum of analyst reactions depict a company with solid near-term operating performance but a range of analyst views on valuation and momentum.
Summary of key facts:
- Insider transaction: CFO sold 1,000 shares on April 1, 2026, at $224.31 per share for $224,310.
- Post-transaction ownership: Sandercock holds 83,495 shares directly.
- Market context: ResMed trading at $224.09 with a $32.5 billion market capitalization.
- Financial results: Q2 fiscal 2026 EPS of $2.81 vs. $2.73 expected; revenue $1.4 billion in line with forecasts.
- Analyst moves: Price target increases from RBC and KeyBanc; Hold ratings from Needham and Stifel with notes on growth and user survey insights.